Barclays
CCCC icon

Barclays’s C4 Therapeutics CCCC Stock Holding History

Barclays’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Sell
74,516
-243,361
-77% -$832K ﹤0.01% 3405
2026
Q1 		$836K Buy
317,877
+98,673
+45% +$232K ﹤0.01% 2859
2025
Q4 		$419K Buy
219,204
+176,142
+409% +$417K ﹤0.01% 3939
2025
Q3 		$95.6K Sell
43,062
-2,761
-6% -$6.63K ﹤0.01% 4629
2025
Q2 		$65.5K Sell
45,823
-61,697
-57% -$89.7K ﹤0.01% 4662
2025
Q1 		$172K Sell
107,520
-14,845
-12% -$44.3K ﹤0.01% 4136
2024
Q4 		$441K Sell
122,365
-121,092
-50% -$602K ﹤0.01% 3899
2024
Q3 		$1.39M Buy
243,457
+67,546
+38% +$406K ﹤0.01% 3132
2024
Q2 		$813K Buy
175,911
+122,818
+231% +$732K ﹤0.01% 2727
2024
Q1 		$434K Buy
53,093
+9,478
+22% +$73.5K ﹤0.01% 3678
2023
Q4 		$246K Buy
43,615
+1
+0% +$2 ﹤0.01% 4328
2023
Q3 		$81.1K Buy
43,614
+10,246
+31% +$31.3K ﹤0.01% 3674
2023
Q2 		$91.8K Sell
33,368
-13,995
-30% -$45K ﹤0.01% 3596
2023
Q1 		$149K Sell
47,363
-56,285
-54% -$331K ﹤0.01% 3963
2022
Q4 		$612K Buy
103,648
+28,408
+38% +$236K ﹤0.01% 3176
2022
Q3 		$660K Buy
75,240
+71,244
+1,783% +$740K ﹤0.01% 2514
2022
Q2 		$30K Sell
3,996
-23,647
-86% -$208K ﹤0.01% 4242
2022
Q1 		$670K Buy
+27,643
New +$671K ﹤0.01% 2695

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Barclays's CCCC Position: Q2 2026 in Review

Barclays reduced its C4 Therapeutics (CCCC) stake by 77% in Q2 2026, selling an estimated $832K and leaving 74,516 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #3405.

Barclays first reported a position in CCCC in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.39M in Q3 2024. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Barclays held 74,516 shares of C4 Therapeutics worth $348K as of Q2 2026.
  • Barclays sold 243,361 C4 Therapeutics shares in Q2 2026, an estimated $832K.
  • C4 Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3405 holding.
  • Barclays first reported a position in C4 Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's C4 Therapeutics position peaked at $1.39M in Q3 2024.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.